MANNKIND CORP
Nasdaq: MNKDPharmaceutical Preparations · Entity-resolved by Clous
Key financials
Market
Short interest & fails
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The annual report describes a company with durable hardware franchises and a fast-growing, high-margin services segment. Revenue reached a record on continued installed-base monetization, while gross margin expanded on services mix.
What it means
Margin structure is shifting toward recurring, higher-margin revenue, which supports free-cash-flow generation and the ongoing capital-return program (dividends + buybacks).
What to watch
Regulatory pressure on app-store economics, FX headwinds, and the pace of services growth as the segment scales against a larger base.
Generated from public filings · not investment advice
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | $99.77M | $198.96M | $285.5M | $348.97M | +22.2% | 100% |
| Net Income | -$87.4M | -$11.94M | $27.59M | $5.86M | -78.7% | 2% |
| Total Assets | $295.28M | $475.2M | $393.84M | $792.18M | +101.1% | 227% |
| Equity | -$250.54M | -$246.17M | -$78.82M | -$51.02M | +35.3% | -15% |
| Operating Cash Flow | -$80.68M | $34.09M | $42.51M | $18.26M | -57.1% | 5% |
| Shares Outstanding | — | — | — | 308.1M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0000899460